{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:18:33Z","timestamp":1761110313213},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.aprim.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T21:46:18Z","timestamp":1492465578000},"page":"492-497","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Queratosis act\u00ednica: nuevo concepto y actualizaci\u00f3n terap\u00e9utica"],"prefix":"10.1016","volume":"49","author":[{"given":"Rafael","family":"Carmena-Ram\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Mateu-Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Santos-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Lucas-Truyols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2017.01.004_bib0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ad.2009.11.007","article-title":"Motivos de consulta dermatol\u00f3gicos en la poblaci\u00f3n inmigrante y espa\u00f1ola del \u00e1rea de salud del Hospital Son Ll\u00e0tzer (Mallorca)","volume":"101","author":"Taberner","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.aprim.2017.01.004_bib0160","unstructured":"Prevalence of Actinic Keratosis in Spain. Epidemiological study (EPIQA): published European International Congress."},{"key":"10.1016\/j.aprim.2017.01.004_bib0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.piel.2014.11.010","article-title":"Queratosis act\u00ednicas: un modelo de campo de cancerizaci\u00f3n","volume":"30","author":"Garc\u00eda","year":"2015","journal-title":"Piel (Barc)."},{"issue":"Supl.","key":"10.1016\/j.aprim.2017.01.004_bib0170","article-title":"Factores etiol\u00f3gicos y epidemiol\u00f3gicos de las queratosis act\u00ednicas","volume":"27","author":"Ballester S\u00e1nchez","year":"2014","journal-title":"Monogr Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0175","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: A systematic review","volume":"169","author":"Werner","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0180","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin","volume":"29","author":"Fern\u00e1ndez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"Suppl 66","key":"10.1016\/j.aprim.2017.01.004_bib0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.0366-077X.2003.05625.x","article-title":"Pathology and pathobiology of the actinic (solar) keratosis","volume":"149","author":"Cockerell","year":"2003","journal-title":"Br J Dermatol."},{"issue":"Supl 1","key":"10.1016\/j.aprim.2017.01.004_bib0190","first-page":"21","article-title":"Evoluci\u00f3n de las queratosis act\u00ednicas: de la piel normal al carcinoma y sus posibles met\u00e1stasis","volume":"27","author":"V\u00e1zquez Veiga","year":"2014","journal-title":"Monogr Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0195","first-page":"1462","article-title":"The paradigm shift in treating actinic keratosis: A comprehensive strategy","volume":"11","author":"Stockfleth","year":"2012","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0200","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-4632.2004.02056.x","article-title":"A prospective study of the use of cryosurgery for the treatment of actinic keratosis","volume":"43","author":"Thai","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.aprim.2017.01.004_bib0205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09546630903341937","article-title":"Comparision of topical 5-fluorouracil formulations in actinic keratosis treatment","volume":"21","author":"Kaur","year":"2010","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.aprim.2017.01.004_bib0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis. A systematic review of randomized controlled trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/09546630902789326","article-title":"Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders","volume":"20","author":"Moore","year":"2009","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.aprim.2017.01.004_bib0220","first-page":"35","article-title":"Non-adherence to topical treatments for actinic keratosis","volume":"8","author":"Shergill","year":"2013","journal-title":"Patient Prefer Adherence."},{"key":"10.1016\/j.aprim.2017.01.004_bib0225","first-page":"741","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results","volume":"13","author":"Berman","year":"2014","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0230","series-title":"Terapia Fotodin\u00e1mica","author":"Gilaberte","year":"2008"},{"key":"10.1016\/j.aprim.2017.01.004_bib0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1684\/ejd.2013.1923","article-title":"Therapeutic strategies for actinic keratosis: A systematic review","volume":"23","author":"Nashan","year":"2013","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdv.12031","article-title":"European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications-actinic keratoses, Bowen's disease, basal cell carcinoma","volume":"27","author":"Morton","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0245","first-page":"CD004415","article-title":"Interventions for actinic keratosis (Review)","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.aprim.2017.01.004_bib0250","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2017.01.004_bib0255","unstructured":"Garbe C. Ingenol mebutate gel 0.015% repeat use for multiple actinic keratoses on face and scalp: A 12 month phase 3 clinical study. Presentado en el World Congress on Cancers of the Skin, Edimburgo,Escocia. 4 de septiembre de 2014."},{"key":"10.1016\/j.aprim.2017.01.004_bib0260","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","article-title":"Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses","volume":"149","author":"Lebwohl","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0265","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.12343","article-title":"Network meta-analysis of the outcome \u2018participant complete clearance\u2019 in non-immunosuppressed participants of eight interventions for actinic keratosis: A follow-up on a Cochrane review","volume":"169","author":"Gupta","year":"2013","journal-title":"Br J Dermatol."},{"issue":"Suppl 2","key":"10.1016\/j.aprim.2017.01.004_bib0270","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0275","unstructured":"Ficha t\u00e9cnica. Aldara\u00ae."},{"key":"10.1016\/j.aprim.2017.01.004_bib0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2340\/00015555-0213","article-title":"Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel","volume":"87","author":"Rivers","year":"2007","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0290","first-page":"20","article-title":"Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: One-year evaluation","volume":"2","author":"Nelson","year":"2009","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0295","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","article-title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles","volume":"62","author":"Swanson","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.aprim.2017.01.004_bib0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ijd.12840","article-title":"A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis","volume":"54","author":"Stockfleth E1","year":"2015","journal-title":"Int J Dermatol."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656717301440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656717301440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T16:42:16Z","timestamp":1601916136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656717301440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0212656717301440"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2017.01.004","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Queratosis act\u00ednica: nuevo concepto y actualizaci\u00f3n terap\u00e9utica","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2017.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}